Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: A cross-sectional, controlled study of carotid ultrasound

Rheumatology (United Kingdom)

Volumn 53, Issue 4, 2014, Pages 704-713

  Schiopu, Elena ^a   Au, Karen M ^b   Mcmahon, Maureen A ^c   Kaplan, Mariana J ^c   Divekar, Anagha ^c   Singh, Ram R ^c   Furst, Daniel E ^c   Clements, Philip J ^c   Ragvendra, Nagesh ^c   Zhao, Wenpu ^c   Maranian, Paul ^c   Khanna, Dinesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Carotid intima media thickness; Endothelial dysfunction; Serum proteins; Systemic sclerosis; Type I interferon

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CLARA CELL PROTEIN; ENDOGLIN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE A; KERATINOCYTE GROWTH FACTOR; LOW DENSITY LIPOPROTEIN; MYELOID PROGENITOR INHIBITORY FACTOR 1; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; SOMATOMEDIN BINDING PROTEIN 3; THROMBOMODULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY ULTRASOUND; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART MUSCLE FIBROSIS; HUMAN; MIDDLE AGED; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; ULTRASOUND; ULTRASOUND TRANSDUCER; VASCULAR DISEASE;

ATHEROSCLEROSIS; CAROTID INTIMA MEDIA THICKNESS; ENDOTHELIAL DYSFUNCTION; SERUM PROTEINS; SYSTEMIC SCLEROSIS; TYPE I INTERFERON;

ADULT; ANTIGENS, CD; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHEMOKINES, CC; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 7; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-2; INTERLEUKIN-6; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PLAQUE, ATHEROSCLEROTIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; RISK FACTORS; SCLERODERMA, SYSTEMIC; SERUM AMYLOID A PROTEIN; THROMBOMODULIN; UTEROGLOBIN;

EID: 84897867507     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket411     Document Type: Article

References (49)

1. Asanuma Y, Oeser A, Shintani A et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
2. Rho Y, Chung C, Oeser A et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;61:1580-85.
3. Soltész P, Kerekes G, De'r H et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011;10:416-25.
4. O'Neill S, Giles I, Lambrianides A et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:845-54.
5. McMahon M, Grossman J, Skaggs B et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428-37.
6. Borba E, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-9.
7. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
8. Ihn H, Sato S, Fujimoto M et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000;119:203-9.
9. Hou Y, Rabquer B, Gerber M et al. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis 2010;69:249-54.
10. Manetti M, Guiducci S, Ibba-Manneschi L et al. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010;14:1241-54.
11. Tyrrell P, Beyene J, Feldman B et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30:1014-26.
12. Au K, Singh M, Bodukam V et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum 2011;63:2078-90.
13. Ngian G, Sahhar J, Proudman S et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 2012;71:1980-3.
14. Man A, Zhu Y, Zhang Y et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis 2013;72:1188-93.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
16. Ansell B, Navab M, Hama S et al. Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6.
17. Denny M, Thacker S, Mehta H et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907-15.
18. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011;10:259-66.
19. D'Angelo W, Fries J, Masi A et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
20. Youssef P, Brama T, Englert H et al. Limited scleroderma is associated with increased prevalence of macrovascular disease. J Rheumatol 1995;22:469-72.
21. Salonen R, Haapanen A, Salonen J. Measurement of intima-media thickness of common carotid arteries with high-resolution B-mode ultrasonography: inter- and intra-observer variability. Ultrasound Med Biol 1991;17:225-30.
22. Zureik M, Ducimetie' re P, Touboul P et al. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study. Arterioscler Thromb Vasc Biol 2000;20:1622-9.
23. Störk S, van den Beld A, von Schacky C et al. Carotid artery plaque burden, stiffness, and mortality risk in elderly men: a prospective, population-based cohort study. Circulation 2004;110:344-8.
24. Khurma V, Meyer C, Park G et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum 2008;59:591-7.
25. Tarek e-G, Yasser A, Gheita T. Coronary angiographic findings in asymptomatic systemic sclerosis. Clin Rheumatol 2006;25:487-90.
26. del Sol A, Moons K, Hollander M et al. Is carotid intimamedia thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke 2001;32:1532-8.
27. Pasha S, Wiria A, Wammes L et al. Blood pressure class and carotid artery intima-media thickness in a population at the secondary epidemiological transition. J Hypertens 2011;29:2194-200.
28. Protogerou A, Zampeli E, Fragiadaki K et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011;219:734-6.
29. Kerekes G, Soltész P, Szucs G et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011;13:147-52.
30. Rajarathnam K, Li Y, Rohrer T et al. Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine. J Biol Chem 2001;276:4909-16.
31. Son K, Hwang J, Kwon B et al. Human CC chemokine CCL23 enhances expression of matrix metalloproteinase- 2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun 2006;340:498-504.
32. Kim C, Kang J, Cho H et al. Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes. Inflamm Res 2011;60:889-95.
33. Hermans C, Knoops B, Wiedig M et al. Clara cell protein as a marker of Clara cell damage and bronchoalveolar blood barrier permeability. Eur Resp J 1999;13:1014-21.
34. Hasegawa M, Fujimoto M, Hamaguchi Y et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol 2011;38:877-84.
35. Wang Y, Chen G, Qiao S et al. Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant. Leuk Lymphoma 2011;52:1556-66.
36. Peng C, He Q, Luo C. Lack of keratinocyte growth factor retards angiogenesis in cutaneous wounds. J Int Med Res 2011;39:416-23.
37. Lijnen H. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005;3:35-45.
38. Martin R, Gunnell D, Whitley. et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab 2008;93:1331-8.
39. Hamaguchi Y, Fujimoto M, Matsushita T et al. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008;35:2363-71.
40. Farina G, Lafyatis D, Lemaire R et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2010;62:580-8.
41. McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
42. Charles-Schoeman C, Khanna D, Furst DE et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007;34:1459-64.
43. Navab M, Hama S, Hough G et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17.
44. Szucs G, Ti'már O, Szekanecz Z et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology 2007;46:759-62.
45. LeRoy E, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
46. Higgs B, Liu Z, White B et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
47. Hou Y, Rabquer B, Gerber M et al. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis 2010;69:249-54.
48. Ostermann G, Fraemohs L, Baltus T et al. Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler Thromb Vasc Biol 2005;25:729-35.
49. Cavusoglu E, Kornecki E, Sobocka M et al. Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis. J Am Coll Cardiol 2007;50:1768-76.